A Phase 3 interventional study of tissue plasminogen activator and Saline in Myocardial Infarction and Percutaneous Coronary Intervention, sponsored by Population Health Research Institute. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Population Health Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Myocardial Infarction with a site in Canada — 18 open to participants now, 30 under way, 9 of them phase 3. Myocardial Infarction · Canada.
Among the 171 studies in Myocardial Infarction with a site in Canada, this one is the 86th largest by enrollment of the 135 interventional ones that give a count, is one of 10 that started in 2018, is one of 45 in phase 3, and was the 121st registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →18 of the 171 studies in Myocardial Infarction with a site in Canada are open now. Recruiting first, the newest first:
Montreal Heart Institute · Sites in Canada
Ages 18+
Amgen · Sites in Canada, United States, Australia and 1 more country
Ages 50–105
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
CSL Behring · Sites in Canada, United States, Argentina and 32 more countries
Ages 18+
Laval University · Sites in Canada
Ages 18–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 27 · Phase 3 51 · Phase 4 22
First in 1999; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 500 across the 135 interventional studies, 1,060 across the 36 observational. Of the 119 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 171 have an industry lead sponsor. The 10 most frequent:
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Population Health Research Institute has 8 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
10 of the studies in Myocardial Infarction with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT06174753Phase 3Ottawa Heart Institute Research CorporationDapagliflozin in STEMI | 2027-06 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07171580St. Boniface HospitalTailoring Post Discharge - Remote Education and Access for Cardiac Health | 2026-11-30 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 171 studies in Myocardial Infarction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tissue plasminogen activator
Drug: tissue plasminogen activator
saline
Other: Saline
Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
Placebo
MACE OR Myocardial Blush Grade 0/1 OR Distal Embolization OR Failure to Achieve ≥50% ST-segment Resolution
The primary efficacy variable is the binary composite outcome with the following components: * The occurrence of any of the MACE outcomes (cardiovascular death, myocardial re-infarction, cardiogenic shock and new onset heart failure) at 30 days post-randomization. * Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI). * Failure to achieve ≥50% ST-segment resolution post-procedure.
Time frame: 30 days post-randomization
The Composite of MBG grade 0/1 or Distal Embolization or Failure to Achieve ≥50% ST-segment Resolution
* Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI). * Failure to achieve ≥50% ST-segment resolution post-procedure of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI
Time frame: 30 minutes post-PCI
The Composite of MBG grade 0/1 or Distal Embolization
* Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI).
Time frame: Immediately following PCI
MBG Grade 0/1
Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).
Time frame: Immediately following PCI
Distal Embolization
Post-procedural distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI.
Time frame: Immediately following PCI
Failure to Achieve ≥50% ST-segment Resolution.
Failure to achieve ≥50% ST-segment resolution of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI.
Time frame: 30 minutes post-PCI
Time to the First Occurrence of MACE
Time to the first occurrence of MACE (composite of cardiovascular death, myocardial re-infarction, cardiogenic shock or new onset heart failure) over the duration of 30 days follow-up.
Time frame: 30 days post-randomization
Time to the First Occurrence of Major Bleeding Over the Duration of 30 Days Follow-up
Clinically overt, bleeding with at least one of the following criteria: * Fatal or * Symptomatic intracranial hemorrhage or * Retroperitoneal hemorrhage or * Intraocular hemorrhage leading to significant vision loss or * Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or * Requiring surgical intervention to stop the bleeding
Time frame: 30 days post-randomization
Time to the First Occurrence of Major or Clinically Significant Bleeding Over the Duration of 30 Days Follow-up
Clinically overt, bleeding with at least one of the following criteria: * Fatal or * Symptomatic intracranial hemorrhage or * Retroperitoneal hemorrhage or * Intraocular hemorrhage leading to significant vision loss or * Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or * Requiring surgical intervention to stop the bleeding Any other clinically significant bleeding not meeting the definition for major bleeding and resulting in hospital admission, prolonged hospital stay or transfusion of one unit of blood (whole blood or packed red blood cells (PRBC))
Time frame: 30 days post-randomization
Failure to achieve ≥ 50% resolution
Failure to achieve ≥ 50% resolution of the ST-segment value (worst lead) at 30 minutes post-PCI
Time frame: 30 minutes post-PCI
All-Cause Mortality at 30 Days
The composite of cardiovascular or non-cardiovascular death
Time frame: 30 days post-randomization
Flow Velocity as Measured by the Corrected TIMI Frame Count (Continuous)
Continuous measure of TIMI frame count as reported by Angiographic Core Lab.
Time frame: Immediately following PCI
Post-Procedural TIMI Flow Grade 3
Full perfusion of the infarct vessel with normal flow.
Time frame: Immediately following PCI
Time to the First Occurrence of Composite of Cardiovascular Death (CV), Cardiogenic Shock and New Onset Heart Failure (HF) Over the Duration of 30 Days Follow-up
All deaths with a CV or unknown cause will be classified as CV. Only deaths due to a documented non-CV cause will be classified as non-CV. At least one of the following: * SBP \<90mmHg and not responsive to fluid resuscitation and/or HR correction for at least 1 hr * Need for vasopressor/inotropic therapy to maintain SBP \>90mmHg for at least 1 hr, believed to be secondary to cardiac dysfunction and associated with Pulmonary edema/Hypoperfusion/Cardiac Index \<2.0L/min New onset HF as per NYHA and defined as decision to treat with IV diuretic, inotropic agent or vasodilator with at least one of the following: presence of pulmonary edema or pulmonary vascular congestion on chest radiograph thought to be due to HF / râles reaching above the lower 1/3 of the lung fields thought to be due to HF / pulmonary capillary wedge pressure or left ventricular end-diastolic pressure = 18mmHg. In the case of new onset outpatient HF, re-admission to an acute care facility is required.
Time frame: 30 days post-randomization
Plan to share: Undecided
Ran from Apr 2018 to primary completion in Sep 2024, 77 months.
Of 34 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's 77 months is above that.
Counting every sponsor, half of 58 studies reached it within 44 months; a quarter within 30 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tissue Plasminogen Activator
Population Health Research Institute →